These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 30118338)

  • 1. The nocebo effect: a clinical challenge in the era of biosimilars.
    Pouillon L; Socha M; Demore B; Thilly N; Abitbol V; Danese S; Peyrin-Biroulet L
    Expert Rev Clin Immunol; 2018 Sep; 14(9):739-749. PubMed ID: 30118338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Consensus report: clinical recommendations for the prevention and management of the nocebo effect in biosimilar-treated IBD patients.
    Pouillon L; Danese S; Hart A; Fiorino G; Argollo M; Selmi C; Carlo-Stella C; Loeuille D; Costanzo A; Lopez A; Vegni E; Radice S; Gilardi D; Socha M; Fazio M; González-Lorenzo M; Bonovas S; Magro F; Peyrin-Biroulet L
    Aliment Pharmacol Ther; 2019 May; 49(9):1181-1187. PubMed ID: 30932219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multidisciplinary management of the nocebo effect in biosimilar-treated IBD patients: Results of a workshop from the NOCE-BIO consensus group.
    D'Amico F; Pouillon L; Argollo M; Hart A; Fiorino G; Vegni E; Radice S; Gilardi D; Fazio M; Leone S; Bonovas S; Magro F; Danese S; Peyrin-Biroulet L
    Dig Liver Dis; 2020 Feb; 52(2):138-142. PubMed ID: 31812570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biosimilar switching in inflammatory bowel disease: from evidence to clinical practice.
    Solitano V; D'Amico F; Fiorino G; Peyrin-Biroulet L; Danese S
    Expert Rev Clin Immunol; 2020 Oct; 16(10):1019-1028. PubMed ID: 32954893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The nocebo effect challenges the non-medical infliximab switch in practice.
    Boone NW; Liu L; Romberg-Camps MJ; Duijsens L; Houwen C; van der Kuy PHM; Janknegt R; Peeters R; Landewé RBM; Winkens B; van Bodegraven AA
    Eur J Clin Pharmacol; 2018 May; 74(5):655-661. PubMed ID: 29368188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The nocebo effect and patient perceptions of biosimilars in inflammatory bowel disease.
    Pineles D; Malter L; Liang PS; Arsuaga A; Bosworth B; Hudesman DP; Chang S
    Eur J Clin Pharmacol; 2018 Oct; 74(10):1361-1362. PubMed ID: 29855655
    [No Abstract]   [Full Text] [Related]  

  • 7. Nocebo effect and biosimilars in inflammatory bowel diseases: what's new and what's next?
    D'Amico F; Solitano V; Peyrin-Biroulet L; Danese S
    Expert Opin Biol Ther; 2021 Jan; 21(1):47-55. PubMed ID: 32857634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-pharmacological Effects in Switching Medication: The Nocebo Effect in Switching from Originator to Biosimilar Agent.
    Kristensen LE; Alten R; Puig L; Philipp S; Kvien TK; Mangues MA; van den Hoogen F; Pavelka K; Vulto AG
    BioDrugs; 2018 Oct; 32(5):397-404. PubMed ID: 30269270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. To See or NOsee: The Debate on the Nocebo Effect and Optimizing the Use of Biosimilars.
    Rezk MF; Pieper B
    Adv Ther; 2018 Jun; 35(6):749-753. PubMed ID: 29873005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Nocebo Effect in a Non-Medical Switching Program from Originator to Biosimilar Infliximab in Inflammatory Bowel Disease.
    Dutt K; Srinivasan A; Van Langenberg D
    BioDrugs; 2022 Sep; 36(5):639-644. PubMed ID: 35960446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Just Say No…to the Nocebo Effect.
    Rossmann L; Cross RK
    Inflamm Bowel Dis; 2020 Apr; 26(5):669. PubMed ID: 32031637
    [No Abstract]   [Full Text] [Related]  

  • 12. Biosimilars in IBD: Will it Benefit to Patients, Physicians or the Health Care System?
    Gonczi L; Ilias A; Kurti Z; Lakatos PL
    Curr Pharm Des; 2019; 25(1):13-18. PubMed ID: 30864504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical efficacy and nocebo effect following non-medical biosimilar switch in patients with inflammatory bowel disease: A prospective observational study.
    Wetwittayakhlang P; Karkout K; Wongcha-Um A; Tselekouni P; Al-Jabri R; Afif W; Wild G; Bitton A; Bessissow T; Lakatos PL
    Dig Liver Dis; 2024 Jan; 56(1):35-42. PubMed ID: 37419726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Biosimilars and the nocebo effect].
    Braun J; Tsiami S; Buehring B; Kiefer D; Andreica I; Baraliakos X; Kiltz U
    Z Rheumatol; 2020 Apr; 79(3):267-275. PubMed ID: 31802197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Editorial: nocebo effect and switching to biosimilars.
    van Bodegraven AA; Boone NW
    Aliment Pharmacol Ther; 2018 Mar; 47(6):850-851. PubMed ID: 29446141
    [No Abstract]   [Full Text] [Related]  

  • 16. Progress with infliximab biosimilars for inflammatory bowel disease.
    Kurti Z; Gonczi L; Lakatos PL
    Expert Opin Biol Ther; 2018 Jun; 18(6):633-640. PubMed ID: 29688797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are we ready to close the discussion on the interchangeability of biosimilars?
    Ebbers HC; Schellekens H
    Drug Discov Today; 2019 Oct; 24(10):1963-1967. PubMed ID: 31254488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug Discontinuation in Studies Including a Switch From an Originator to a Biosimilar Monoclonal Antibody: A Systematic Literature Review.
    Bakalos G; Zintzaras E
    Clin Ther; 2019 Jan; 41(1):155-173.e13. PubMed ID: 30551802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biosimilars for inflammatory bowel disease: how can healthcare professionals help address patients' concerns?
    Gecse KB; Cumming F; D'Haens G
    Expert Rev Gastroenterol Hepatol; 2019 Feb; 13(2):143-155. PubMed ID: 30791783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential Cost Implications of Mandatory Non-Medical Switching Policies for Biologics for Rheumatic Conditions and Inflammatory Bowel Disease in Canada.
    Crosby M; Tadrous M; Gomes T
    Clin Pharmacol Ther; 2021 Mar; 109(3):739-745. PubMed ID: 32909249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.